Our Commercialised Products

Acrux has successfully developed and commercialised a portfolio of topical and transdermal pharmaceutical products through established international partnerships.

The portfolio includes hormone therapies and topical generic medicines, demonstrating the Company's drug development and commercialisation expertise.

A woman at home smiling at her phone

Hormone Therapy Products

EVAMIST estradiol transdermal spray

EVAMIST®

Estradiol transdermal spray developed by Acrux for the treatment of moderate to severe hot flushes associated with menopause.

Commercial partner: Padagis
Market: United States
LENZETTO estradiol transdermal spray

LENZETTO®

Estradiol transdermal spray developed by Acrux for the treatment of moderate to severe hot flushes associated with menopause.

Commercial partner: Gedeon Richter
Markets: Europe and other international markets

Topical Pharmaceutical Products

Dapsone 5% Gel packaging

Dapsone 5% Gel

An FDA-approved topical generic treatment for acne vulgaris.

Commercial partner: TruPharma
Market: United States
Dapsone 7.5% Gel packaging

Dapsone 7.5% Gel

An FDA-approved topical generic treatment for acne vulgaris.

Commercial partner: TruPharma
Market: United States
Nitroglycerine 0.4% Ointment packaging

Nitroglycerine 0.4% Ointment

An FDA-approved topical generic treatment for pain associated with chronic anal fissures.

Commercial partner: TruPharma
Market: United States